Combination of Cisplatin, Docetaxel and Bevacizumab in Patients With Non-small Cell Lung Carcinoma (NSCLC)

Inclusion Criteria:

• Histologically or cytologically documented inoperable, locally advanced, metastatic or recurrent NSCLC other than squamous cell
• At least 1 measurable lesion according to RECIST criteria
• ECOG performance score 0 or 1
• Age between 18 and 70 years

Exclusion Criteria:

• Mixed, non-small cell and small cell tumours or mixed adenosquamous carcinomas with a predominant squamous component.
• History of haemoptysis
• Evidence of tumour invading major blood vessels on imaging.
• Previous neoadjuvant/adjuvant chemotherapy.
• Previous radiotherapy.
• Serious uncontrolled coagulation disorder or thrombo-embolic complications within 6 months prior to study start or history of serious bleeding complications.
• Major surgical procedures within 4 weeks prior to study entry.
• Minor surgery, including insertion of an indwelling catheter, within 24 hours prior to the first bevacizumab infusion.
• Non-healing wound, active peptic ulcer or bone fracture.
• History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrolment.